Future drug development may focus on several key areas, including SCFA-targeted delivery systems, NRF2/PPAR-γ pathway-specific agonists, and metabolic reprogramming regulators, employing multi-target intervention strategies to address obesity-related male infertility. The gene discussed is PPARG; the disease is obesity due to melanocortin 4 receptor deficiency.